Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyJavier Cortés, Chris Twelves, Denis Mir et al.|The Lancet|2011Cited by 1.1k
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast CancerKimberly Blackwell, Joyce O’Shaughnessy|Journal of Clinical Oncology|2010Cited by 960
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancerAditya Bardia, Sara A. Hurvitz, Sara M. Tolaney et al.|Annals of Oncology|2021Cited by 294
The Progress and Promise of Molecular Imaging Probes in Oncologic Drug DevelopmentGary J. Kelloff, Janet Woodcock, Kenneth A. Krohn et al.|Clinical Cancer Research|2005Cited by 220
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightnessOtto Metzger, Daniel G. Stover, Katharine A. Collier et al.|npj Breast Cancer|2021Cited by 37